Known
CA II deficiency is a rare genetic condition
It is linked to pathogenic CA2 variants with autosomal recessive inheritance, as summarized on About and Sources.
Evidence and limits
A conservative summary from existing site themes (About, Treatment, Sources, Global evidence). Not individualized clinical advice.
Clear themes already stated on the site.
Literature signals without individual rules.
Explicit gaps without an approved solution.
Known
It is linked to pathogenic CA2 variants with autosomal recessive inheritance, as summarized on About and Sources.
Known
Many reports associate the condition with increased bone density, renal tubular acidosis, and cerebral calcification — not always present at the same severity.
Known
The treatment page summarizes acid–base/electrolyte support and organ-focused follow-up. The treating team decides the plan; there is no one protocol for everyone.
Known
Published reports are limited; skeletal disease may improve while renal tubular acidosis may persist. Not standard care for all patients.
Uncertain
Published examples (e.g., hypomorphic vs more severe loss-of-function patterns) exist, but they are not individual rules and do not set doses or protocols.
Uncertain
Acid–base support is used clinically, but long-term CA II–specific studies remain limited, as noted in treatment gaps.
Research needed
No published trials link a specific CA2 variant to a specific drug or guaranteed response.
Research needed
No approved gene therapy or enzyme replacement for CA II appears in the site’s current content.
Research needed
Residual activity is a useful literature concept but is not routinely measured in every clinic.
More detail: Treatment page gaps · Research gaps · Academic library